Ronald H. W. M. Derksen chercheur néerlandais
Derksen, R.H.W.M. (Ronald Henricus Wilhelmus Maria), 1949-
Derksen, R. H. W. M.
Derksen, R.H.W.M. 1949-
VIAF ID: 283678183 (Personal)
Permalink: http://viaf.org/viaf/283678183
Preferred Forms
4xx's: Alternate Name Forms (10)
Works
| Title | Sources |
|---|---|
| Deposition of nucleosomal antigens (histones and DNA) in the epidermal basement membrane in human lupus nephritis |
|
| Determination of antibodies against double-stranded DNA; when and which test? |
|
| Dimers of beta 2-glycoprotein I mimic the in vitro effects of beta 2-glycoprotein I-anti-beta 2-glycoprotein I antibody complexes |
|
| Discordant effects of prednisone on anticardiolipin antibodies and the lupus anticoagulant |
|
| [Disseminated lupus erythematosus and pregnancy] |
|
| The effect of dehydroepiandrosterone on lumbar spine bone mineral density in patients with quiescent systemic lupus erythematosus |
|
| The efficacy of plasma exchange in the removal of plasma components |
|
| A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). |
|
| Haematopoietic and endothelial progenitor cells are deficient in quiescent systemic lupus erythematosus |
|
| Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine/ methylprednisolone in a randomized controlled trial. |
|
| Heat treatment of serum and plasma induces false positive results in the antiphospholipid antibody ELISA |
|
| How to treat women with antiphospholipid antibodies in pregnancy? |
|
| IgG subclass distribution of autoantibodies differs between renal and extra-renal relapses in patients with systemic lupus erythematosus |
|
| In vivo antinuclear antibody of the skin: diagnostic significance and association with selective antinuclear antibodies |
|
| Induction therapy with short-term high-dose intravenous cyclophosphamide followed by mycophenolate mofetil in proliferative lupus nephritis. |
|
| International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop |
|
| Interobserver agreement of scoring of histopathological characteristics and classification of lupus nephritis. |
|
| Leerboek immunologie, 2016: |
|
| Low levels of activated protein C in patients with systemic lupus erythematosus do not relate to lupus anticoagulants but to low levels of factor II |
|
| Lupus anticoagulant: an old phenomenon in a new perspective |
|
| Lupus anticoagulant in cardiovascular diseases: the role of beta2-glycoprotein I. |
|
| Measurement of antinuclear antibodies and their fine specificities: time for a change in strategy? |
|
| Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients |
|
| New developments in lupus-associated antiphospholipid syndrome |
|
| De nierbiopsie |
|
| Pathophysiology of thrombotic APS: where do we stand? |
|
| Patient‐derived monoclonal antibodies directed towards beta2 glycoprotein‐1 display lupus anticoagulant activity |
|
| Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment |
|
| Persistent increase in plasma thrombomodulin in patients with a history of lupus nephritis: endothelial cell activation markers. |
|
| Plasma exchange in the treatment of cryoglobulinaemia |
|
| Platelet activation by dimeric beta2-glycoprotein I requires signaling via both glycoprotein Ibalpha and apolipoprotein E receptor 2'. |
|
| Polymyalgia rheumatica and temporal arteritis |
|
| Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus |
|
| The presence of anti-beta 2-glycoprotein I and anti-prothrombin antibodies and their correlations with venous and arterial thrombosis |
|
| The presence of antiphospholipid antibodies is not related to increased levels of annexin A5 in plasma |
|
| The prevalence and clinical associations of the lupus anticoagulant in systemic lupus erythematosus. |
|
| Primary antiphospholipid syndrome evolving into systemic lupus erythematosus |
|
| The "primary" antiphospholipid syndrome: major clinical and serological features. |
|
| Prolonged bleeding time and lupus anticoagulant: a second paradox in the antiphospholipid syndrome |
|
| Prospective multicentre trial on the short-term effects of plasma exchange versus cytotoxic drugs in steroid-resistant lupus nephritis. |
|
| Psychological and somatic predictors of perceived and measured ocular dryness of patients with primary Sjögren's syndrome |
|
| Rapidly fatal HTLV-1-associated T-cell leukemia/lymphoma in a patient with SLE. |
|
| Reply |
|
| Risk factors for thrombosis in lupus patients |
|
| The role of LRP8 (ApoER2') in the pathophysiology of the antiphospholipid syndrome |
|
| Sclerodermie |
|
| Serum dehydroepiandrosterone sulphate levels and laboratory and clinical parameters indicating expression of disease are not associated with fatigue, well-being and functioning in patients with primary Sjögren's syndrome. |
|
| Somatic mutations in the variable regions of a human IgG anti-double-stranded DNA autoantibody suggest a role for antigen in the induction of systemic lupus erythematosus |
|
| Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002. |
|
| Structure-function studies on beta 2-glycoprotein I. |
|
| Het syndroom van Sjögren |
|
| Tests for lupus anticoagulant revisited |
|
| Therapy of proliferative lupus glomerulonephritis: a prospective trial in The Netherlands |
|
| Thrombosis associated with antiphospholipid antibodies cannot be explained by effects on endothelial and platelet prostanoid synthesis |
|
| Towards evidence-based treatment of thrombotic antiphospholipid syndrome |
|
| [Treatment of nephritis in systemic lupus erythematodes] |
|
| The use of glucocorticoids in systemic lupus erythematosus. After 60 years still more an art than science |
|
| Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxis |
|
| প্রত্যুত্তর |
|
